| Assessment Status | Rapid Review Complete |
| HTA ID | 20042 |
| Drug | Infliximab |
| Brand | Remsima® SC |
| Indication | For treatment of adult patients with Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis in line with the adult indications of the IV formulation. |
| Assessment Process | |
| Rapid review commissioned | 23/09/2020 |
| Rapid review completed | 15/10/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Remsima SC not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations March 2022.
